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ARDS = acute respiratory distress syndrome; COPD = chronic obstructive pulmonary disease; FIO2 = fraction of inspired O2; Gfb = gain due to
feedback; HPV = hypoxic pulmonary vasoconstriction; NO = nitric oxide; PAO2 = alveolar PO2; Ppa = pulmonary artery pressure; PVR = pulmonary
vascular resistance; VA = alveolar ventilation.
Available online http://ccforum.com/content/5/2/067
What is hypoxic pulmonary vasoconstriction?
Pulmonary hypertension as a result of asphyxia has been
observed since the beginning of this century, but the first
convincing evidence of hypoxic pulmonary vasoconstric-
tion (HPV) together with a still valid functional interpreta-
tion was reported by von Euler and Liljestrand in 1946 [1].
These authors ventilated anesthetized cats with either
hypoxic (fraction of inspired O2 [FIO2], 0.1) or hypercap-
nic (fraction of inspired CO2, up to 19.6%) gas mixtures,
and found that both interventions increased pulmonary
artery pressure (Ppa) without change in left atrial pressure.
Hypoxia increased Ppa proportionally more than hypercap-
nia in these experiments. Pulmonary blood flow (Q) was
not measured, and the possible explanation that at least
part of the changes in Ppa could have been caused by
hypoxia-induced or hypercapnia-induced increases in
cardiac output was not taken into consideration. In the dis-
cussion of their results, the authors noted that “… oxygen
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want and carbon dioxide accumulation have exactly the
reverse effects on the systemic and pulmonary circulations
respectively; in both cases, however, they seem to be
adapted for their special purposes. They cause a dilatation
of the vessels in the working organs which need a greater
blood supply than during rest, but they call for a contrac-
tion of the lung vessels, thereby increasing the blood flow
to better aerated lung areas, which leads to improved con-
ditions for the utilization of alveolar air” [1].
According to this view, in lung parenchyma, local PO2 is
determined by a ratio between oxygen delivery to the
lungs, or alveolar ventilation (VA), and oxygen delivery from
the lungs to the systemic tissues, or perfusion (Q):
PO2 = VA/Q
In systemic tissues, however, local PO2 is determined by a
ratio between oxygen delivery to the tissues, or perfusion
(Q), and local oxygen consumption (VO2):
PO2 = Q/VO2
It has now been better appreciated that alveolar hypoxia
indeed increases the gradient between Ppa and left
atrial pressure independently of associated changes in
cardiac output, thus increasing pulmonary vascular resis-
tance (PVR), but that CO2 has two opposing actions on
pulmonary vascular tone. These actions are a direct
relaxing effect and a constricting effect mediated by a
decrease in pH [2].
Fifty years after the initial report of von Euler and Liljes-
trand, the basic attributes of HPV can be summarized as
follows [3–5]. HPV occurs within seconds of the onset of
alveolar hypoxia. HPV can be observed in isolated perfused
lungs, pulmonary artery rings denuded of endothelium, and
in single pulmonary artery smooth muscle cells. HPV
seems to decrease with age, and exhibits marked inter-
species and interindividual differences. The magnitude of
HPV in vivo is inversely proportional to lung segment size.
The main determinant of HPV is alveolar PO2 (PAO2), but
mixed venous PO2 contributes to approximately one fifth of
the response. HPV is inhibited by a variety of mediators
present in the blood or released from lung parenchyma,
such as substance P, calcitonine gene-related peptide, and
atrial natriuretic peptides, by endothelium-derived vasodila-
tors such as prostacyclin and nitric oxide (NO), by a -
adrenergic blockade, by b-adrenergic stimulation, by
increased left atrial pressure, by increased alveolar pres-
sure, by alkalosis, and by peripheral chemoreceptor stimu-
lation. HPV is enhanced by acidosis, by ab-adrenergic
blockade, by epidural blockade, by low-dose serotonin, and
by the inhibition of cyclooxygenase (aspirin, indomethacin) or
NO synthase (L-arginine analogs). These latter two effects
indicate that HPV is attenuated acutely by endogenous NO
and prostacyclin. HPV can be inhibited by a series of
vasodilating drugs including calcium channel blockers and
halogenated anesthetics, and can be enhanced by the
peripheral chemoreceptor stimulant almitrine and the
appetite suppressant fenfluramines.
Hypoxic vasoconstriction mainly occurs in small pre-
capillary arterioles [3–5] but small pulmonary veins also
constrict in response to hypoxia, although not to more
than 20% of the total change in PVR [6]. An exaggerated
hypoxic pulmonary venoconstriction could explain certain
forms of pulmonary edema, such as high altitude pul-
monary edema, which is initially caused by an increase in
pulmonary capillary pressure [7].
The cellular mechanism of HPV
Numerous studies have been devoted to the mechanism
responsible for relating pulmonary vascular tone to
changes in PO2. A series of vasoconstrictors including
histamine, serotonin, angiotensin, prostaglandins, and
leukotrienes have been excluded as potential mediators.
The hypothesis that hypoxia initiates pulmonary vasocon-
striction by a reduction of high-energy phosphates has not
been confirmed. Other hypotheses, including cytochrome
P450 as a sensor of the decrease in PO2 triggering pul-
monary vasoconstriction, or HPV as a result of the inhibi-
tion of endogenous vasodilator mediators such as NO,
have also not been confirmed [5].
It has recently been shown that pulmonary vascular
smooth muscle cells and type I cells of the carotid body
share the ability to sense changes in PO2. Hypoxia has
been demonstrated in both cells to inhibit outward potas-
sium current, causing membrane depolarization and
calcium entry through the voltage-dependent calcium
channels [5]. There is evidence in both cells to suggest
that changes in the redox status of the oxygen-sensitive
potassium channels may control the current flow, so that
the channel is open when oxidized and closed when
reduced [5]. Two such oxygen-sensitive potassium chan-
nels, Kv2.1 and Kv1.5, have been identified in rat pulmonary
arteries [8]. In systemic arteries, hypoxia causes an inward
current through ATP-dependent potassium channels and
vasodilatation. Profound hypoxia also dilates pulmonary
arteries by the same mechanism.
Stimulus–response curves for HPV
The relationship between FIO2 or PAO2 and HPV,
expressed as a change in Ppa at a given flow or as an
amount of flow diversion at a given Ppa, has been gener-
ally found in experimental animal preparations to be either
sigmoid [9] or linear [10] in shape, with a continued con-
striction as long as FiO2 or PAO2 was decreased.
However, in isolated in vivo pig lungs at constant flow, in
which particular attention was paid to reaching a steady
state before each measurement, the Ppa–PAO2 curvec
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was shown to be biphasic, with a maximum at PAO2
between 30 and 60 Torr, and a down sloping portion, or
hypoxic pulmonary vasodilation, at lower PAO2 [11]. In
dogs, a species with a pulmonary vasoreactivity to hypoxia
comparable with that of man [4], the relationship between
FIO2 progressively decreased from 1 to 0.06, and Ppa
measured at a constant Q has also been shown to be
biphasic, with a down sloping portion at a FIO2 lower than
0.1, corresponding to a PaO2 of 36–38 Torr [12]. Evi-
dence of hypoxic pulmonary vasodilation in man was
obtained during Operation Everest II [13], in which normal
subjects were decompressed in a hypobaric chamber for
40 days to an atmospheric pressure (Pb) equivalent to the
summit of Mount Everest. The subjects presented an
average Ppa of 34 mmHg at rest and of 54 mmHg at exer-
cise at a Pb of 282 Torr (7620 m; resting PaO2, 37 Torr),
that decreased to 33 and 48 mmHg, respectively, at a Pb
of 240 Torr (8840 m; resting PaO2, 30 Torr) [13].
The efficiency of HPV
Grant et al [10] used the equations of control theory and
the linear relationships between lobar blood flow and
PAO2 found in the Coatimundi, an animal with a strong
hypoxic pressor response, to calculate the efficiency of
HPV as a mechanism to stabilize PAO2. They found a gain
due to feedback (Gfb) of a maximum of 0.9 at a PAO2
between 60 and 80 Torr, rapidly falling off outside these
values. A Gfb of 0.9 represents an active correction of
47% of the decrease in PAO2 that would occur in a
passive system without HPV. Mélot et al [14] used the
same equations and linear relationships between compart-
mental blood flow and PAO2 derived from inert gas elimina-
tion data obtained in healthy volunteers, and found a
maximum Gfb of 0.63 at a PAO2 of 60 Torr, also rapidly
falling off at lower and at higher PAO2. A Gfb of 0.63 rep-
resents an active correction by 39% of a decrease in PAO2
that would occur in a passive system without HPV. These
studies suggested that the hypoxic pressor response is
only a moderately efficient feedback mechanism, acting
essentially at PAO2 values higher than known to occur in
severe lung diseases. The studies even supported the
speculation that HPV would be merely some fetal remnant
and not useful in extra-uterine life. However, more recent
evaluations of the efficiency of hypoxic pressor response
using a multicompartment lung model [15] fed by real data
biphasic stimulus–response curves [16] have led to the
conclusions that HPV is really effective in improving gas
exchange in severe respiratory insufficiency.
A quantification of the efficiency of HPV in terms of correc-
tion of arterial hypoxemia in either decompensated chronic
obstructive pulmonary disease (COPD) or acute respira-
tory distress syndrome (ARDS) is presented in Figure 1.
Patients with COPD are hypoxemic because of increased
dispersion of the distributions of perfusion and ventilation,
with increased perfusion to lung units with a lower than
normal VA/Q value [17,18]. Altered pulmonary gas
exchange in these patients can thus be quantified by the
logarithm of the standard deviation of VA/Q dispersion,
whereas the strength of HPV can be expressed as Ppa in
hypoxia divided by Ppa in hyperoxia at constant flow [16].
The magnitude of HPV ranges normally from 1 to 4 in the
canine and in the human species. It can be seen that, in
COPD, PaO2 may increase by up to 20 mmHg through the
effects of vigorous HPV. This is indeed the range of PaO2
observed in these patients from enhanced HPV by almitrine
[17] to inhibited HPV by nifedipine [18].
Patients with ARDS are hypoxemic mainly because of an
increased shunt [19,20]. Altered gas exchange in these
patients can thus be quantified by intrapulmonary shunt,
expressed in percent of cardiac output. Figure 1 shows
that, in ARDS, PaO2 may increase by as much as
20 mmHg owing to vigorous HPV. This is in keeping with
the magnitude of decreases in arterial oxygenation
observed in patients with ARDS due to inhibition of HPV
by diltiazem [19] or prostaglandin E1 [20].
Recent positron emission tomography can studies in
experimental oleic acid lung injury clearly show an
increased perfusion in the most dependent lung regions,
together with an important decrease in PaO2 when HPV is
ablated by a minute amount of endotoxin [21]. The results
of a typical experiment are shown in Figure 2. The deterio-
ration in PaO2 by the inhibition of HPV in this experimental
ARDS model conforms to multicompartment lung HPV
model predictions [22].
HPV in acute lung injury
HPV has been reported inhibited in some models of acute
lung injury. As already mentioned, HPV is preserved in
Available online http://ccforum.com/content/5/2/067
Figure 1
Effects of HPV in COPD, a lung disease characterized by VA/Q
mismatching, and in ARDS, a disease characterized by an increased
shunt. LogSD VA/Q, logarithmic standard deviation of lognormal VA/Q
distribution. FIO2 was set at 0.3 in COPD and 0.4 in ARDS.
(Reproduced with permission from [16].)oleic acid lung injury but can be ablated by minute amounts
of endotoxin. That HPV is still operative in most patients
with ARDS is indicated by the clinical observation of acute
pulmonary hypertension at accidental interruption of artifi-
cial ventilation, and by the hypoxemic effects of intra-
venously administered vasodilator drugs that inhibit HPV
[19,20]. The persistence of active pulmonary vascular tone
is also shown by the effects of inhaled vasodilators such as
NO [23] or prostacyclin [24], which increase PaO2
because of an improved VA/Q matching by a redistribution
of perfusion to the lung regions with the highest VA/Q
value. These observations have led to attempts of correc-
tion of hypoxemia in patients with ARDS by a combination
of inhaled vasodilators to vasodilate the most healthy lung
regions, and by intravenous constrictors to vasoconstrict
the most diseased lung regions [25,26]. However, until
now there has been no demonstration of clinical benefit of
improved gas exchange by pharmacological manipulation
of HPV. This is probably due to the fact that an increase in
arterial oxygenation by pharmacological enhancement of
HPV would be of clinical relevance only in situations of life-
threatening hypoxemia. Most patients with ARDS do not
die from asphyxia, but from multiple organ failure.
Effects of anesthesia
Spinal anesthesia has been shown to enhance HPV [27],
but the clinical relevance of this observation is uncertain.
Intravenous anesthetics have generally been found to be
without any effect on HPV [28]. Inhaled anesthetics have
been reported to inhibit HPV in a variety of in vitro experi-
mental preparations [28]. For example, in isolated rat
lungs  in vitro, halothane, enflurane, and isoflurane inhibit
the hypoxic pressor response to the same extent at identi-
cal concentrations expressed as minimal alveolar concen-
trations units, with a 50% effective dose of approximately
0.6 [29]. In more intact animal preparations and in
patients, however, higher concentrations than minimal
alveolar concentration 1 are needed to inhibit HPV [30].
Conclusions
Pharmacological manipulations of HPV are feasible, and
are associated with important changes in pulmonary gas
exchange and in arterial oxygenation. The clinical rele-
vance of this fascinating physiological phenomenon
remains to be properly assessed.
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